Risk and Timing of Venous Thromboembolism After Surgery for Lung Cancer : A Nationwide Cohort Study
Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Venous thromboembolism (VTE) is a potentially preventable serious complication in patients with lung cancer undergoing thoracic operation. We examined the risk and timing of VTE after surgery for primary non-small cell lung cancer (NSCLC).
METHODS: All patients undergoing operation for NSCLC in Denmark between 2003 and 2021 were identified in the Danish Lung Cancer Registry. VTE events in the year after operation were assessed by stage, patient characteristics, and surgical procedure.
RESULTS: We identified 13,197 patients who underwent operation for NSCLC in 2003 to 2021 (mean age, 67.6 years; 50% female); 10,524 (79.7%) had stage I-II NSCLC, and 2673 (20.3%) had stage III-IV. During 1-year follow-up, there were 335 VTE events, yielding a rate of 2.87 events/100 person-years and an absolute risk of 3.3% (95% CI, 2.3-4.0). VTE risk increased with advancing cancer stage (1.8% for stage I vs 3.9% for stage IV) but varied little by pathologic type, sex, and comorbidity level. Bilobectomy was associated with highest VTE risk (4.8%; 95% CI, 3.2-6.9), followed by pneumonectomy (3.5%; 95% CI, 2.3-5.0). The hazard of VTE was highest during the first 3 months after operation, after which it declined. For stage IV cancer, hazards increased again after 6 months. At 1 year, all-cause death was 12.6% (95% CI, 12.0%-13.1%).
CONCLUSIONS: VTE developed in 3.3% of patients undergoing operation for NSCLC, most commonly within 3 months postoperatively. Prolonged thromboprophylaxis could be considered, particularly in those with advanced cancer stage and undergoing extended resections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
The Annals of thoracic surgery - 117(2024), 2 vom: 15. Jan., Seite 289-296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mørkved, Amalie Lambert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.athoracsur.2023.10.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363828796 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363828796 | ||
| 003 | DE-627 | ||
| 005 | 20240115231904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.athoracsur.2023.10.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM363828796 | ||
| 035 | |a (NLM)37890818 | ||
| 035 | |a (PII)S0003-4975(23)01073-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mørkved, Amalie Lambert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk and Timing of Venous Thromboembolism After Surgery for Lung Cancer |b A Nationwide Cohort Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Venous thromboembolism (VTE) is a potentially preventable serious complication in patients with lung cancer undergoing thoracic operation. We examined the risk and timing of VTE after surgery for primary non-small cell lung cancer (NSCLC) | ||
| 520 | |a METHODS: All patients undergoing operation for NSCLC in Denmark between 2003 and 2021 were identified in the Danish Lung Cancer Registry. VTE events in the year after operation were assessed by stage, patient characteristics, and surgical procedure | ||
| 520 | |a RESULTS: We identified 13,197 patients who underwent operation for NSCLC in 2003 to 2021 (mean age, 67.6 years; 50% female); 10,524 (79.7%) had stage I-II NSCLC, and 2673 (20.3%) had stage III-IV. During 1-year follow-up, there were 335 VTE events, yielding a rate of 2.87 events/100 person-years and an absolute risk of 3.3% (95% CI, 2.3-4.0). VTE risk increased with advancing cancer stage (1.8% for stage I vs 3.9% for stage IV) but varied little by pathologic type, sex, and comorbidity level. Bilobectomy was associated with highest VTE risk (4.8%; 95% CI, 3.2-6.9), followed by pneumonectomy (3.5%; 95% CI, 2.3-5.0). The hazard of VTE was highest during the first 3 months after operation, after which it declined. For stage IV cancer, hazards increased again after 6 months. At 1 year, all-cause death was 12.6% (95% CI, 12.0%-13.1%) | ||
| 520 | |a CONCLUSIONS: VTE developed in 3.3% of patients undergoing operation for NSCLC, most commonly within 3 months postoperatively. Prolonged thromboprophylaxis could be considered, particularly in those with advanced cancer stage and undergoing extended resections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Søgaard, Mette |e verfasserin |4 aut | |
| 700 | 1 | |a Skjøth, Flemming |e verfasserin |4 aut | |
| 700 | 1 | |a Ording, Anne Gulbech |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Torben Bjerregaard |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobsen, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Højen, Anette Arbjerg |e verfasserin |4 aut | |
| 700 | 1 | |a Noble, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Meldgaard, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Rene Horsleben |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Thomas Decker |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Annals of thoracic surgery |d 1965 |g 117(2024), 2 vom: 15. Jan., Seite 289-296 |w (DE-627)NLM000026689 |x 1552-6259 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:289-296 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.athoracsur.2023.10.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2024 |e 2 |b 15 |c 01 |h 289-296 | ||